Go Pro
→ Your book is inside (From Profits Run) (Ad)tc pixel Free HRTX Stock Alerts

Heron Therapeutics (HRTX) Competitors

Heron Therapeutics logo
$0.34 +0.00 (+0.69%)
Closing price 04:00 PM Eastern
Extended Trading
$0.35 +0.01 (+3.06%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

HRTX vs. SLGL, SBTX, NERV, ANTX, and ACB

Should you buy Heron Therapeutics stock or one of its competitors? Heron Therapeutics's main competitors and comparable companies include Sol-Gel Technologies (SLGL), Silverback Therapeutics (SBTX), Minerva Neurosciences (NERV), Anthem (ANTX), and Aurora Cannabis (ACB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Heron Therapeutics compare to Sol-Gel Technologies?

Sol-Gel Technologies (NASDAQ:SLGL) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Sol-Gel Technologies has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

Sol-Gel Technologies has higher earnings, but lower revenue than Heron Therapeutics. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sol-Gel Technologies$19.39M12.27-$6.13M-$0.34N/A
Heron Therapeutics$154.90M0.41-$20.19M-$0.19N/A

Sol-Gel Technologies currently has a consensus price target of $197.50, indicating a potential upside of 133.20%. Heron Therapeutics has a consensus price target of $2.00, indicating a potential upside of 494.00%. Given Heron Therapeutics' higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than Sol-Gel Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sol-Gel Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.67
Heron Therapeutics
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Heron Therapeutics had 17 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 21 mentions for Heron Therapeutics and 4 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.80 beat Heron Therapeutics' score of -0.36 indicating that Sol-Gel Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sol-Gel Technologies
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Heron Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral

26.2% of Sol-Gel Technologies shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by insiders. Comparatively, 6.1% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Sol-Gel Technologies has a net margin of -5.66% compared to Heron Therapeutics' net margin of -22.52%. Sol-Gel Technologies' return on equity of -3.17% beat Heron Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sol-Gel Technologies-5.66% -3.17% -2.58%
Heron Therapeutics -22.52%-293.02%-10.00%

Summary

Sol-Gel Technologies beats Heron Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Heron Therapeutics compare to Silverback Therapeutics?

Silverback Therapeutics (NASDAQ:SBTX) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

In the previous week, Heron Therapeutics had 21 more articles in the media than Silverback Therapeutics. MarketBeat recorded 21 mentions for Heron Therapeutics and 0 mentions for Silverback Therapeutics. Silverback Therapeutics' average media sentiment score of 0.00 beat Heron Therapeutics' score of -0.36 indicating that Silverback Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Silverback Therapeutics Neutral
Heron Therapeutics Neutral

Silverback Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market.

Heron Therapeutics has a consensus price target of $2.00, suggesting a potential upside of 494.00%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Silverback Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silverback Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Heron Therapeutics
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Heron Therapeutics has higher revenue and earnings than Silverback Therapeutics. Silverback Therapeutics is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silverback TherapeuticsN/AN/A-$89.48M-$2.42N/A
Heron Therapeutics$154.90M0.41-$20.19M-$0.19N/A

Silverback Therapeutics has a net margin of 0.00% compared to Heron Therapeutics' net margin of -22.52%. Silverback Therapeutics' return on equity of -29.62% beat Heron Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Silverback TherapeuticsN/A -29.62% -28.20%
Heron Therapeutics -22.52%-293.02%-10.00%

74.9% of Silverback Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by company insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Heron Therapeutics beats Silverback Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Heron Therapeutics compare to Minerva Neurosciences?

Heron Therapeutics (NASDAQ:HRTX) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by company insiders. Comparatively, 1.7% of Minerva Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Heron Therapeutics has higher revenue and earnings than Minerva Neurosciences. Heron Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$154.90M0.41-$20.19M-$0.19N/A
Minerva NeurosciencesN/AN/A-$293.42M-$28.87N/A

Heron Therapeutics currently has a consensus target price of $2.00, indicating a potential upside of 494.00%. Minerva Neurosciences has a consensus target price of $10.33, indicating a potential upside of 125.62%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Heron Therapeutics is more favorable than Minerva Neurosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heron Therapeutics
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Minerva Neurosciences
2 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.75

Minerva Neurosciences has a net margin of 0.00% compared to Heron Therapeutics' net margin of -22.52%. Minerva Neurosciences' return on equity of 0.00% beat Heron Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Heron Therapeutics-22.52% -293.02% -10.00%
Minerva Neurosciences N/A N/A -31.72%

Heron Therapeutics has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.1, meaning that its share price is 110% less volatile than the broader market.

In the previous week, Heron Therapeutics had 2 more articles in the media than Minerva Neurosciences. MarketBeat recorded 21 mentions for Heron Therapeutics and 19 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.19 beat Heron Therapeutics' score of -0.36 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Heron Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
Minerva Neurosciences
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Heron Therapeutics beats Minerva Neurosciences on 10 of the 14 factors compared between the two stocks.

How does Heron Therapeutics compare to Anthem?

Heron Therapeutics (NASDAQ:HRTX) and Anthem (NASDAQ:ANTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Heron Therapeutics has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, Anthem has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market.

In the previous week, Heron Therapeutics had 19 more articles in the media than Anthem. MarketBeat recorded 21 mentions for Heron Therapeutics and 2 mentions for Anthem. Anthem's average media sentiment score of 1.48 beat Heron Therapeutics' score of -0.36 indicating that Anthem is being referred to more favorably in the news media.

Company Overall Sentiment
Heron Therapeutics Neutral
Anthem Positive

Heron Therapeutics currently has a consensus price target of $2.00, suggesting a potential upside of 494.00%. Anthem has a consensus price target of $9.00, suggesting a potential upside of 50.25%. Given Heron Therapeutics' higher possible upside, equities analysts plainly believe Heron Therapeutics is more favorable than Anthem.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heron Therapeutics
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Anthem
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Heron Therapeutics has higher revenue and earnings than Anthem. Anthem is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$154.90M0.41-$20.19M-$0.19N/A
AnthemN/AN/A-$35.17M-$1.07N/A

80.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 90.5% of Anthem shares are held by institutional investors. 6.1% of Heron Therapeutics shares are held by insiders. Comparatively, 22.6% of Anthem shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Anthem has a net margin of 0.00% compared to Heron Therapeutics' net margin of -22.52%. Anthem's return on equity of -53.52% beat Heron Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Heron Therapeutics-22.52% -293.02% -10.00%
Anthem N/A -53.52%-48.63%

Summary

Heron Therapeutics beats Anthem on 8 of the 15 factors compared between the two stocks.

How does Heron Therapeutics compare to Aurora Cannabis?

Heron Therapeutics (NASDAQ:HRTX) and Aurora Cannabis (NASDAQ:ACB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Heron Therapeutics has a net margin of -22.52% compared to Aurora Cannabis' net margin of -32.26%. Aurora Cannabis' return on equity of 4.37% beat Heron Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Heron Therapeutics-22.52% -293.02% -10.00%
Aurora Cannabis -32.26%4.37%3.45%

Heron Therapeutics presently has a consensus target price of $2.00, suggesting a potential upside of 494.00%. Given Heron Therapeutics' higher probable upside, equities analysts clearly believe Heron Therapeutics is more favorable than Aurora Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heron Therapeutics
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Aurora Cannabis
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

80.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are held by institutional investors. 6.1% of Heron Therapeutics shares are held by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Heron Therapeutics has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

Heron Therapeutics has higher earnings, but lower revenue than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$154.90M0.41-$20.19M-$0.19N/A
Aurora Cannabis$247.82M0.96-$88.13M-$1.41N/A

In the previous week, Aurora Cannabis had 2 more articles in the media than Heron Therapeutics. MarketBeat recorded 23 mentions for Aurora Cannabis and 21 mentions for Heron Therapeutics. Aurora Cannabis' average media sentiment score of 0.62 beat Heron Therapeutics' score of -0.36 indicating that Aurora Cannabis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Heron Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aurora Cannabis
8 Very Positive mention(s)
3 Positive mention(s)
8 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Heron Therapeutics and Aurora Cannabis tied by winning 8 of the 16 factors compared between the two stocks.

Get Heron Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HRTX vs. The Competition

Export
MetricHeron TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$63.49M$11.89B$7.06B$13.10B
Dividend YieldN/A2.70%2.57%10.45%
P/E Ratio-1.77640.15211.0921.74
Price / Sales0.41743.87602.9892.99
Price / CashN/A66.4570.4850.90
Price / Book11.2211.6012.916.24
Net Income-$20.19M$2.77B$3.45B$347.60M
7 Day Performance-31.40%0.17%1.12%1.07%
1 Month Performance-21.68%0.35%1.79%1.03%
1 Year Performance-75.06%161.52%67.69%20.77%

Heron Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HRTX
Heron Therapeutics
1.9418 of 5 stars		$0.34
+0.7%		$2.00
+494.0%		-76.1%$63.49M$154.90MN/A300
SLGL
Sol-Gel Technologies
3.8996 of 5 stars		$84.58
-0.2%		$197.50
+133.5%		+443.9%$236.70M$19.39MN/A50
SBTX
Silverback Therapeutics
N/A$6.16
+11.0%		N/A-63.7%$222.12MN/AN/A83
NERV
Minerva Neurosciences
1.8283 of 5 stars		$4.65
+0.6%		$10.50
+125.8%		+116.6%$216.64MN/AN/A9
ANTX
Anthem
2.5243 of 5 stars		$6.00
+1.4%		$9.00
+50.1%		+458.9%$216.30MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:HRTX) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Who Really Gets Rich from IPOs?
Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...
Weiss Ratings | Sponsoredtc pixel
$100 for this… $500 for that. Here’s how to stop the bleeding today
Rising costs are squeezing households nationwide. USA Today reports more families are moving in together, whil...
Brownstone Research | Sponsoredtc pixel